{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Goyzueta-Mamani LD"],"funding":["Universidad Catolica de Santa Maria","ProCiencia"],"pagination":["173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11722285"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(1)"],"pubmed_abstract":["Leishmaniasis, a neglected tropical disease caused by <i>Leishmania</i> species, presents serious public health challenges due to limited treatment options, toxicity, high costs, and drug resistance. In this study, the in vitro potential of malvidin and echioidinin is examined as antileishmanial agents against <i>L. amazonensis</i>, <i>L. braziliensis</i>, and <i>L. infantum</i>, comparing their effects to amphotericin B (AmpB), a standard drug. Malvidin demonstrated greater potency than echioidinin across all parasite stages and species. Against <i>L. amazonensis</i>, malvidin's IC<sub>50</sub> values were 197.71 ± 17.20 µM (stationary amastigotes) and 258.07 ± 17 µM (axenic amastigotes), compared to echioidinin's 272.99 ± 29.90 μM and 335.96 ± 19.35 μM. AmpB was more potent, with IC<sub>"],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis and In Vitro Efficacy."],"pmcid":["PMC11722285"],"funding_grant_id":["27499-R-2020, 27574-R-2020, 7309-CU-2020, and 28048-R-2021","PE501088204-2024"],"pubmed_authors":["Paco-Chipana M","Galdino AS","Pagliara Lage D","Cordeiro Giunchetti R","Chavez-Fumagalli MA","Barazorda-Ccahuana HL","Davila-Del-Carpio G","Goyzueta-Mamani LD","Candia-Puma MA","D'Antonio EL","Ferraz Coelho EA","Machado-de-Avila RA"],"additional_accession":[]},"is_claimable":false,"name":"Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis and In Vitro Efficacy.","description":"Leishmaniasis, a neglected tropical disease caused by <i>Leishmania</i> species, presents serious public health challenges due to limited treatment options, toxicity, high costs, and drug resistance. In this study, the in vitro potential of malvidin and echioidinin is examined as antileishmanial agents against <i>L. amazonensis</i>, <i>L. braziliensis</i>, and <i>L. infantum</i>, comparing their effects to amphotericin B (AmpB), a standard drug. Malvidin demonstrated greater potency than echioidinin across all parasite stages and species. Against <i>L. amazonensis</i>, malvidin's IC<sub>50</sub> values were 197.71 ± 17.20 µM (stationary amastigotes) and 258.07 ± 17 µM (axenic amastigotes), compared to echioidinin's 272.99 ± 29.90 μM and 335.96 ± 19.35 μM. AmpB was more potent, with IC<sub>","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-04-08T18:29:44.049Z","creation":"2026-04-08T09:27:15.35Z"},"accession":"S-EPMC11722285","cross_references":{"pubmed":["39795229"],"doi":["10.3390/molecules30010173"]}}